• Laura

Featured Innovator: Eloxx

Featured Innovator :: Eloxx

Eloxx Pharmaceuticals is a clinical stage company developing therapeutics for the treatment of genetic disease caused by non-sense mutations. To summarize the science, where there is genetic disease or birth defects, there are shorter-than-normal proteins in the affected gene. Eloxx’s science enables the creation of full-length proteins.

Eloxx’s lead compound, ELX-02 has potential to be the first disease-modifying therapy for treatment of these devastating diseases, for which there are no effective treatments. ELX-02 is currently in Phase I and Phase II testing for five genetic diseases, and has other preclinical tests in the pipeline.

Eloxx raised $24 million in a Series C financing in June 2017 which will be used to initiate more clinical studies. Chinese investors included GF Securities and the Catalyst CEL Fund. The company merged with Sevion Therapeutics Inc. a week before the financing and plans to apply to list on Nasdaq.

Sources: Globes, Eloxx and Catalyst

Back to this week's features.

0 views

Recent Posts

See All

Data = GOLD

What do you think of when someone talks about data? Your 4G plan? The Matrix? Or do you mentally check out of that geek-talk? Data isn’t always some boring alien language. In fact it is the most direc

Newsletter – 2018-11-07

7 November 2018 Hi everyone, It's expo time! Shanghai is buzzing this week as the business world descends on the megopolis to realize their hopes and dreams in China. I expect to have more news next w

© 2020 by China Deals InfoBase, a division of Lohtsman.
Proudly created with Wix.com